|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Seiwert TY and Cohen EE: State-of-the-art
management of locally advanced head and neck cancer. Br J Cancer.
92:1341–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forastiere AA, Goepfert H, Maor M, et al:
Concurrent chemotherapy and radiotherapy for organ preservation in
advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dietz A, Boehm A, Mozet C, Wichmann G and
Giannis A: Current aspects of targeted therapy in head and neck
tumors. Eur Arch Otorhinolaryngol. 265(Suppl 1): S3–S12. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Price KA and Cohen EE: Current treatment
options for metastatic head and neck cancer. Curr Treat Options
Oncol. 13:35–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kirby AM, A’Hern RP, D’Ambrosio C, et al:
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or
metastatic head and neck cancer. Br J Cancer. 94:631–636.
2006.PubMed/NCBI
|
|
7
|
Herbst RS, Arquette M, Shin DM, et al:
Phase II multicenter study of the epidermal growth factor receptor
antibody cetuximab and cisplatin for recurrent and refractory
squamous cell carcinoma of the head and neck. J Clin Oncol.
23:5578–5587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimamura T, Royal RE, Kioi M, Nakajima A,
Husain SR and Puri RK: Interleukin-4 cytotoxin therapy synergizes
with gemcitabine in a mouse model of pancreatic ductal
adenocarcinoma. Cancer Res. 67:9903–9912. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ishige K, Shoda J, Kawamoto T, et al:
Potent in vitro and in vivo antitumor activity of
interleukin-4-conjugated Pseudomonas exotoxin against human
biliary tract carcinoma. Int J Cancer. 123:2915–2922. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pastan I, Hassan R, Fitzgerald DJ and
Kreitman RJ: Immunotoxin therapy of cancer. Nat Rev Cancer.
6:559–565. 2006. View
Article : Google Scholar
|
|
11
|
Weber F, Asher A, Bucholz R, et al: Safty,
tolerability, and tumor response of IL4-Pseudomonas exotoxin
(NBI-3001) in patients with recurrent malignant glioma. J
Neurooncol. 64:125–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Attia P, Powell DJ Jr, Maker AV, Kreitman
RJ, Pastan I and Rosenberg SA: Selective elimination of human
regulatory T lymphocytes in vitro with the recombinant immunotoxin
LMB-2. J Immunother. 29:208–214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choudhary S, Mathew M and Verma RS:
Therapeutic potential of anticancer immunotoxins. Drug Discov
Today. 16:495–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kohno M, Horibe T, Haramoto M, et al: A
novel hybrid peptide targeting EGFR-expressing cancers. Eur J
Cancer. 47:773–783. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garland L, Gitlitz B, Ebbinghaus S, et al:
Phase I trial of intravenous IL-4 Pseudomonas exotoxin
protein (NBI-3001) in patients with advanced solid tumors that
express the IL-4 receptor. J Immunother. 28:376–381.
2005.PubMed/NCBI
|
|
16
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
17
|
Goon PK, Stanley MA, Ebmeyer J, et al: HPV
& head and neck cancer: a descriptive update. Head Neck Oncol.
1:362009.
|
|
18
|
Bosch F and Rosich L: The contributions of
Paul Ehrlich to pharmacology: a tribute on the occasion of the
centenary of his Nobel Prize. Pharmacology. 82:171–179. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pastan I, Hassan R, FitzGerald DJ and
Kreitman RJ: Immunotoxin treatment of cancer. Annu Rev Med.
221–237. 2007. View Article : Google Scholar
|
|
20
|
Kreitman RJ: Immunotoxins for targeted
cancer therapy (review). AAPS J. 8:532–551. 2006. View Article : Google Scholar
|
|
21
|
Li Z, Yu T, Zhao P and Ma J: Immunotoxins
and cancer therapy. Cell Mol Immunol. 2:106–112. 2005.PubMed/NCBI
|
|
22
|
Horibe T, Kohno M, Haramoto M, Ohara K and
Kawakami K: Designed hybrid TPR peptide targeting Hsp90 as a novel
anticancer agent. J Transl Med. 9:82011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tada N, Horibe T, Haramoto M, Ohara K,
Kohno M and Kawakami K: A single replacement of histidine to
arginine in EGFR-lytic hybrid peptide demonstrates the improved
anticancer activity. Biochem Biophys Res Commun. 407:383–388. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Strome SE, Kawakami K, Alejandro D, et al:
Interleukin 4 receptor-directed cytotoxin therapy for human head
and neck squamous cell carcinoma in animal models. Clin Cancer Res.
8:281–286. 2002.PubMed/NCBI
|
|
25
|
Mehrotra R, Varricchio F, Husain SR and
Puri RK: Head and neck cancers, but not benign lesions, express
interleukin-4 receptors in situ. Oncol Rep. 5:45–48.
1998.PubMed/NCBI
|
|
26
|
Kawakami K, Leland P and Puri RK:
Structure, function, and targeting of interleukin 4 receptors on
human head and neck cancer cells. Cancer Res. 60:2981–2987.
2000.PubMed/NCBI
|
|
27
|
Mimeault M, Hauke R, Mehta PP and Batra
SK: Recent advances in cancer stem/progenitor cell research:
therapeutic implications for overcoming resistance to the most
aggressive cancers. J Cell Mol Med. 11:981–1011. 2007. View Article : Google Scholar : PubMed/NCBI
|
